- Shire (SHPG +1.4%) plans to ask the FDA to approve the ADHD drug Vyvanse for the treatment of newly-recognized binge eating disorder.
- Late-stage studies show Vyvanse outperformed placebo in cutting the number of binge-eating days per week.
- A filing is expected in Q3 2014.
- Deutsche (as quoted by Reuters) says "the market opportunity in BED will likely be hard to gauge for some time." Naturally, Deutsche then proceeds to gauge the market opportunity. Their prediction: $220M BED specific sales in 2017.